Invention Grant
- Patent Title: Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
-
Application No.: US16340318Application Date: 2017-10-06
-
Publication No.: US11666595B2Publication Date: 2023-06-06
- Inventor: Tamara Thelemann , Frank Jaschinski , Richard Klar
- Applicant: Secarna Pharmaceuticals GmbH & Co. KG
- Applicant Address: DE Marburg
- Assignee: Secarna Pharmaceuticals GmbH & Co. KG
- Current Assignee: Secarna Pharmaceuticals GmbH & Co. KG
- Current Assignee Address: DE Marburg
- Agency: Verrill Dana, LLP
- Priority: EP 002166 2016.10.07
- International Application: PCT/EP2017/075511 2017.10.06
- International Announcement: WO2018/065589A 2018.04.12
- Date entered country: 2019-04-08
- Main IPC: A61K31/7125
- IPC: A61K31/7125 ; C12N15/113
Abstract:
The present invention relates to a novel approach for treating cancer, which is based on targeting PD-L1 mRNA. The invention is directed to oligonucleotides comprising 10 to 20 modified or unmodified nucleotides complementary to specifically selected regions of the PD-L1.
Public/Granted literature
- US20200009181A1 Novel Approach for Treating Cancer Public/Granted day:2020-01-09
Information query
